Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

GLP-1R signaling neighborhoods associate with the susceptibility to adverse drug reactions of incretin mimetics.

Autor: Wright SC; Department of Physiology & Pharmacology, Karolinska Institutet, Stockholm, Sweden. shane.wright@ki.se.; Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, H3T 1J4, Canada. shane.wright@ki.se.; Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, QC, H3T 1J4, Canada. shane.wright@ki.se., Motso A; Department of Physiology & Pharmacology, Karolinska Institutet, Stockholm, Sweden., Koutsilieri S; Department of Physiology & Pharmacology, Karolinska Institutet, Stockholm, Sweden., Beusch CM; Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, 17177, Sweden., Sabatier P; Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, 17177, Sweden.; Novo Nordisk Foundation Centre for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2200, Copenhagen, Denmark.; Department of Surgical Sciences, Uppsala University, Uppsala, 75185, Sweden., Berghella A; Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; Faculty of Bioscience and Agro-Food and Environmental Technology, University of Teramo, Teramo, 64100, Italy., Blondel-Tepaz É; Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, H3T 1J4, Canada.; Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, QC, H3T 1J4, Canada., Mangenot K; Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, H3T 1J4, Canada.; Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, QC, H3T 1J4, Canada., Pittarokoilis I; Department of Physiology & Pharmacology, Karolinska Institutet, Stockholm, Sweden., Sismanoglou DC; Department of Physiology & Pharmacology, Karolinska Institutet, Stockholm, Sweden., Le Gouill C; Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, H3T 1J4, Canada., Olsen JV; Novo Nordisk Foundation Centre for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, 2200, Copenhagen, Denmark., Zubarev RA; Chemistry I, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm, 17177, Sweden.; Department of Pharmacological & Technological Chemistry, I.M. Sechenov First Moscow State Medical University, Moscow, 119146, Russia.; The National Medical Research Center for Endocrinology, Moscow, 115478, Russia., Lambert NA; Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta University, Augusta, GA, 30912, USA., Hauser AS; Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Bouvier M; Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, QC, H3T 1J4, Canada. michel.bouvier@umontreal.ca., Lauschke VM; Department of Physiology & Pharmacology, Karolinska Institutet, Stockholm, Sweden. volker.lauschke@ki.se.; Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany. volker.lauschke@ki.se.; University of Tübingen, Tübingen, Germany. volker.lauschke@ki.se.

Publikováno v: Nature communications [Nat Commun] 2023 Oct 09; Vol. 14 (1), pp. 6243. Date of Electronic Publication: 2023 Oct 09.

Michaelis-Menten Quantification of Ligand Signaling Bias Applied to the Promiscuous Vasopressin V2 Receptor.

Autor: Heydenreich FM; Laboratory of Biomolecular Research, Villigen, Switzerland (F.M.H., A.R., D.M., D.B.V.); Department of Biology, Paul Scherrer Institute, Zürich, Switzerland (F.M.H., A.R., D.M., D.B.V.); Department of Biochemistry and Molecular Medicine, Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec, Canada (F.M.H., B.P., J.Z., B.B., C.L., M.B.); MRC Laboratory of Molecular Biology, Cambridge, United Kingdom (F.M.H.); The Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom (B.P.); Department of Structural and Computational Biology, Max Perutz Laboratories, University of Vienna, Vienna, Austria (D.M.); Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (A.I.); Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands, United Kingdom (D.B.V.); and Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom (D.B.V.) franziskah@mrc-lmb.cam.ac.uk michel.bouvier@umontreal.ca dmitry.veprintsev@nottingham.ac.uk., Plouffe B; Laboratory of Biomolecular Research, Villigen, Switzerland (F.M.H., A.R., D.M., D.B.V.); Department of Biology, Paul Scherrer Institute, Zürich, Switzerland (F.M.H., A.R., D.M., D.B.V.); Department of Biochemistry and Molecular Medicine, Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec, Canada (F.M.H., B.P., J.Z., B.B., C.L., M.B.); MRC Laboratory of Molecular Biology, Cambridge, United Kingdom (F.M.H.); The Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom (B.P.); Department of Structural and Computational Biology, Max Perutz Laboratories, University of Vienna, Vienna, Austria (D.M.); Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (A.I.); Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands, United Kingdom (D.B.V.); and Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom (D.B.V.)., Rizk A; Laboratory of Biomolecular Research, Villigen, Switzerland (F.M.H., A.R., D.M., D.B.V.); Department of Biology, Paul Scherrer Institute, Zürich, Switzerland (F.M.H., A.R., D.M., D.B.V.); Department of Biochemistry and Molecular Medicine, Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec, Canada (F.M.H., B.P., J.Z., B.B., C.L., M.B.); MRC Laboratory of Molecular Biology, Cambridge, United Kingdom (F.M.H.); The Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom (B.P.); Department of Structural and Computational Biology, Max Perutz Laboratories, University of Vienna, Vienna, Austria (D.M.); Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (A.I.); Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands, United Kingdom (D.B.V.); and Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom (D.B.V.)., Milić D; Laboratory of Biomolecular Research, Villigen, Switzerland (F.M.H., A.R., D.M., D.B.V.); Department of Biology, Paul Scherrer Institute, Zürich, Switzerland (F.M.H., A.R., D.M., D.B.V.); Department of Biochemistry and Molecular Medicine, Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec, Canada (F.M.H., B.P., J.Z., B.B., C.L., M.B.); MRC Laboratory of Molecular Biology, Cambridge, United Kingdom (F.M.H.); The Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom (B.P.); Department of Structural and Computational Biology, Max Perutz Laboratories, University of Vienna, Vienna, Austria (D.M.); Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (A.I.); Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands, United Kingdom (D.B.V.); and Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom (D.B.V.)., Zhou J; Laboratory of Biomolecular Research, Villigen, Switzerland (F.M.H., A.R., D.M., D.B.V.); Department of Biology, Paul Scherrer Institute, Zürich, Switzerland (F.M.H., A.R., D.M., D.B.V.); Department of Biochemistry and Molecular Medicine, Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec, Canada (F.M.H., B.P., J.Z., B.B., C.L., M.B.); MRC Laboratory of Molecular Biology, Cambridge, United Kingdom (F.M.H.); The Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom (B.P.); Department of Structural and Computational Biology, Max Perutz Laboratories, University of Vienna, Vienna, Austria (D.M.); Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (A.I.); Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands, United Kingdom (D.B.V.); and Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom (D.B.V.)., Breton B; Laboratory of Biomolecular Research, Villigen, Switzerland (F.M.H., A.R., D.M., D.B.V.); Department of Biology, Paul Scherrer Institute, Zürich, Switzerland (F.M.H., A.R., D.M., D.B.V.); Department of Biochemistry and Molecular Medicine, Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec, Canada (F.M.H., B.P., J.Z., B.B., C.L., M.B.); MRC Laboratory of Molecular Biology, Cambridge, United Kingdom (F.M.H.); The Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom (B.P.); Department of Structural and Computational Biology, Max Perutz Laboratories, University of Vienna, Vienna, Austria (D.M.); Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (A.I.); Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands, United Kingdom (D.B.V.); and Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom (D.B.V.)., Le Gouill C; Laboratory of Biomolecular Research, Villigen, Switzerland (F.M.H., A.R., D.M., D.B.V.); Department of Biology, Paul Scherrer Institute, Zürich, Switzerland (F.M.H., A.R., D.M., D.B.V.); Department of Biochemistry and Molecular Medicine, Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec, Canada (F.M.H., B.P., J.Z., B.B., C.L., M.B.); MRC Laboratory of Molecular Biology, Cambridge, United Kingdom (F.M.H.); The Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom (B.P.); Department of Structural and Computational Biology, Max Perutz Laboratories, University of Vienna, Vienna, Austria (D.M.); Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (A.I.); Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands, United Kingdom (D.B.V.); and Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom (D.B.V.)., Inoue A; Laboratory of Biomolecular Research, Villigen, Switzerland (F.M.H., A.R., D.M., D.B.V.); Department of Biology, Paul Scherrer Institute, Zürich, Switzerland (F.M.H., A.R., D.M., D.B.V.); Department of Biochemistry and Molecular Medicine, Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec, Canada (F.M.H., B.P., J.Z., B.B., C.L., M.B.); MRC Laboratory of Molecular Biology, Cambridge, United Kingdom (F.M.H.); The Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom (B.P.); Department of Structural and Computational Biology, Max Perutz Laboratories, University of Vienna, Vienna, Austria (D.M.); Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (A.I.); Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands, United Kingdom (D.B.V.); and Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom (D.B.V.)., Bouvier M; Laboratory of Biomolecular Research, Villigen, Switzerland (F.M.H., A.R., D.M., D.B.V.); Department of Biology, Paul Scherrer Institute, Zürich, Switzerland (F.M.H., A.R., D.M., D.B.V.); Department of Biochemistry and Molecular Medicine, Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec, Canada (F.M.H., B.P., J.Z., B.B., C.L., M.B.); MRC Laboratory of Molecular Biology, Cambridge, United Kingdom (F.M.H.); The Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom (B.P.); Department of Structural and Computational Biology, Max Perutz Laboratories, University of Vienna, Vienna, Austria (D.M.); Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (A.I.); Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands, United Kingdom (D.B.V.); and Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom (D.B.V.) franziskah@mrc-lmb.cam.ac.uk michel.bouvier@umontreal.ca dmitry.veprintsev@nottingham.ac.uk., Veprintsev DB; Laboratory of Biomolecular Research, Villigen, Switzerland (F.M.H., A.R., D.M., D.B.V.); Department of Biology, Paul Scherrer Institute, Zürich, Switzerland (F.M.H., A.R., D.M., D.B.V.); Department of Biochemistry and Molecular Medicine, Institute for Research in Immunology and Cancer, Université de Montréal, Montréal, Québec, Canada (F.M.H., B.P., J.Z., B.B., C.L., M.B.); MRC Laboratory of Molecular Biology, Cambridge, United Kingdom (F.M.H.); The Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom (B.P.); Department of Structural and Computational Biology, Max Perutz Laboratories, University of Vienna, Vienna, Austria (D.M.); Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (A.I.); Centre of Membrane Proteins and Receptors (COMPARE), University of Birmingham and University of Nottingham, Midlands, United Kingdom (D.B.V.); and Division of Physiology, Pharmacology and Neuroscience, School of Life Sciences, University of Nottingham, Nottingham, United Kingdom (D.B.V.) franziskah@mrc-lmb.cam.ac.uk michel.bouvier@umontreal.ca dmitry.veprintsev@nottingham.ac.uk.

Publikováno v: Molecular pharmacology [Mol Pharmacol] 2022 Sep; Vol. 102 (3), pp. 139-149. Date of Electronic Publication: 2022 Jul 02.

Structural Elements Directing G Proteins and β-Arrestin Interactions with the Human Melatonin Type 2 Receptor Revealed by Natural Variants.

Autor: Plouffe B; Department of Biochemistry and Molecular Medicine, Université de Montréal, H3T 1J4 Montréal, Québec, Canada.; Institute for Research in Immunology and Cancer, Université de Montréal, H3T 1J4 Montréal, Québec, Canada.; The Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, BT9 7BL Belfast, U.K., Karamitri A; Université de Paris, Institut Cochin, INSERM, CNRS, F-75014 Paris, France., Flock T; Laboratory of Biomolecular Research, Department of Biology and Chemistry, Paul Scherrer Institute, 5232 Villigen, Switzerland.; Department of Biology, ETH Zürich, 8093 Zürich, Switzerland., Gallion JM; Program in Structural and Computational Biology and Molecular Biophysics, Baylor College of Medicine, 77030 Houston, Texas, United States., Houston S; The Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, BT9 7BL Belfast, U.K., Daly CA; The Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, BT9 7BL Belfast, U.K., Bonnefond A; Université de Lille, INSERM/CNRS UMR 1283/8199-EGID, Institut Pasteur de Lille, CHU de Lille, 59045 Lille, France., Guillaume JL; Université de Paris, Institut Cochin, INSERM, CNRS, F-75014 Paris, France., Le Gouill C; Institute for Research in Immunology and Cancer, Université de Montréal, H3T 1J4 Montréal, Québec, Canada., Froguel P; Université de Lille, INSERM/CNRS UMR 1283/8199-EGID, Institut Pasteur de Lille, CHU de Lille, 59045 Lille, France., Lichtarge O; Program in Structural and Computational Biology and Molecular Biophysics, Baylor College of Medicine, 77030 Houston, Texas, United States.; Department of Molecular and Human Genetics, Baylor College of Medicine, 77030 Houston, Texas, United States., Deupi X; Laboratory of Biomolecular Research, Department of Biology and Chemistry, Paul Scherrer Institute, 5232 Villigen, Switzerland.; Condensed Matter Theory Group, Division of Scientific Computing, Theory, and Data, Paul Scherrer Institute, 5232 Villigen, Switzerland., Jockers R; Université de Paris, Institut Cochin, INSERM, CNRS, F-75014 Paris, France., Bouvier M; Department of Biochemistry and Molecular Medicine, Université de Montréal, H3T 1J4 Montréal, Québec, Canada.; Institute for Research in Immunology and Cancer, Université de Montréal, H3T 1J4 Montréal, Québec, Canada.

Publikováno v: ACS pharmacology & translational science [ACS Pharmacol Transl Sci] 2022 Jan 25; Vol. 5 (2), pp. 89-101. Date of Electronic Publication: 2022 Jan 25 (Print Publication: 2022).

Comprehensive Signaling Profiles Reveal Unsuspected Functional Selectivity of δ-Opioid Receptor Agonists and Allow the Identification of Ligands with the Greatest Potential for Inducing Cyclase Superactivation.

Autor: Mansour A; Department of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montréal, Quebec H3T 1J4, Canada.; CHU Sainte-Justine Research Center, Montréal, Quebec H3T 1C5, Canada., Nagi K; College of Medicine, QU Health, Qatar University, P.O. Box 2713, Doha, Qatar., Dallaire P; Department of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montréal, Quebec H3T 1J4, Canada.; CHU Sainte-Justine Research Center, Montréal, Quebec H3T 1C5, Canada., Lukasheva V; Institute for Research in Immunology and Cancer, Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, Quebec H3T 1J4, Canada., Le Gouill C; Institute for Research in Immunology and Cancer, Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, Quebec H3T 1J4, Canada., Bouvier M; Institute for Research in Immunology and Cancer, Department of Biochemistry and Molecular Medicine, Université de Montréal, Montréal, Quebec H3T 1J4, Canada., Pineyro G; Department of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, Montréal, Quebec H3T 1J4, Canada.; CHU Sainte-Justine Research Center, Montréal, Quebec H3T 1C5, Canada.

Publikováno v: ACS pharmacology & translational science [ACS Pharmacol Transl Sci] 2021 Sep 09; Vol. 4 (5), pp. 1483-1498. Date of Electronic Publication: 2021 Sep 09 (Print Publication: 2021).